Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective

Authors Fabio Ferrarese, Gioia Becchimanzi, Massimo Bernardo, Maria Anna Conte, Angela Gioia, et al

Published 8 August 2008 Volume 2008:4(4) Pages 665—671

DOI https://doi.org/10.2147/TCRM.S3919

Review by Single-blind

Peer reviewer comments 2

Fabio Ferrarese1, Gioia Becchimanzi2, Massimo Bernardo3, Maria Anna Conte4, Angela Gioia5, Davide Ottaviani6, Rosa Palomba7, Gianfranco Pedelini8, Laura Rigotti9, Elvira Scelzi10

1Ospedale Ca’Foncello, Treviso; 2Cure Palliative, Terapia Antalgica, Ospedale Civile Pinerolo, Torino; 3Serv. Cure Palliative, Osp. Bolzano, Bolzano; 4Casa di cura “Pineta del Carso”, Aurisina, Trieste; 5Terapia Antalgica, Ospedale S. Chiara, Pisa; 6Ospedale Molinette, Torino; 7AOU Federico II, Napoli; 8Hospice S. Cristoforo Cologna Veneta, Verona; 9Servizio Cure Palliative Rovereto, Trento; 10U.O. di Oncologia Castelfranco Veneto, Treviso, Italy

Objective: To investigate the possible role and tolerability of high-dose (>160 mg/day) oxycodone controlled release (CR) for the treatment of cancer and non-cancer pain.

Design: 227 patients with cancer or non-cancer pain were enrolled in an open-label, multi-center, Italian study in order to assess the adequacy of their existing pain management (using a numerical rating scale [NRS]) and the possible benefit high-dose oxycodone CR may offer patients experiencing uncontrolled pain.

Results: Pain was poorly controlled at baseline, with only 18.1% of patients reporting adequate pain relief (NRS <3.5). All other patients reported uncontrolled pain, with an average NRS of 7.81. At baseline assessment, 47.89% of patients had been in pain for up to 3 months, 32.82% for 3–6 months, and 19.19% for more than 6 months. After baseline assessment, patients were switched to oxycodone CR monotherapy. The starting dose was individualized to each patient and titrated up over a 3- to 4-day period until effective pain management was achieved. Treatment was continued for an average of 37.24 days during the study. Pain control (final mean NRS of 2.85) was attained with an average dose of oxycodone CR 221.84 mg/day. Standard adverse events (including constipations, nausea, and vomiting) were recorded in 39.64% of patients receiving high-dose oxycodone CR monotherapy. Side-effects tended to subside after the initial week of treatment and did not result in any participants leaving the study.

Conclusion: High-dose oxycodone CR can achieve rapid and effective management of moderate to severe cancer and non-cancer pain with minimum side-effects.

Keywords: oxycodone CR, pain, high-dose, opioid, moderate-severe-pain, cancer, noncancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Combating HIV resistance – focus on darunavir

Cécile L Tremblay

Therapeutics and Clinical Risk Management 2008, 4:759-765

Published Date: 8 August 2008

Atripla™ – HIV therapy in one pill

Boris Julg, Johannes R Bogner

Therapeutics and Clinical Risk Management 2008, 4:573-577

Published Date: 6 June 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

Montelukast in the management of allergic rhinitis

Jaime A Lagos, Gailen D Marshall

Therapeutics and Clinical Risk Management 2007, 3:327-332

Published Date: 15 May 2007

Editorial || FREE PAPER ||

Garry Walsh

Therapeutics and Clinical Risk Management 2005, 1:1-1

Published Date: 15 April 2005